User: Guest  Login
Title:

Predicting cardiac electrical response to sodium-channel blockade and Brugada syndrome using polygenic risk scores

Document type:
Article
Author(s):
Tadros, Rafik; Tan, Hanno L.; el Mathari, Sulayman; Kors, Jan A.; Postema, Pieter G.; Lahrouchi, Najim; Beekman, Leander; Radivojkov-Blagojevic, Milena; Amin, Ahmad S.; Meitinger, Thomas; Tanck, Michael W.; Wilde, Arthur A.; Bezzina, Connie R.
Abstract:
Aims Sodium-channel blockers (SCBs) are associated with arrhythmia, but variability of cardiac electrical response remains unexplained. We sought to identify predictors of ajmaline-induced PR and QRS changes and Type I Brugada syndrome (BrS) electrocardiogram (ECG). Methods and results In 1368 patients that underwent ajmaline infusion for suspected BrS, we performed measurements of 26 721 ECGs, dose-response mixed modelling and genotyping. We calculated polygenic risk scores (PRS) for PR interval (PRSPR), QRS duration (PRSQRS), and Brugada syndrome (PRSBrS) derived from published genome-wide association studies and used regression analysis to identify predictors of ajmaline dose related PR change (slope) and QRS slope. We derived and validated using bootstrapping a predictive model for ajmaline-induced Type I BrS ECG. Higher PRSPR, baseline PR, and female sex are associated with more pronounced PR slope, while PRSQRS and age are positively associated with QRS slope (P < 0.01 for all). PRSBrS, baseline QRS duration, presence of Type II or III BrS ECG at baseline, and family history of BrS are independently associated with the occurrence of a Type I BrS ECG, with good predictive accuracy (optimism-corrected C-statistic 0.74). Conclusion We show for the first time that genetic factors underlie the variability of cardiac electrical response to SCB. PRSBrS, family history, and a baseline ECG can predict the development of a diagnostic drug-induced Type I BrS ECG with clinically relevant accuracy. These findings could lead to the use of PRS in the diagnosis of BrS and, if confirmed in population studies, to identify patients at risk for toxicity when given SCB.
Journal title abbreviation:
Eur Heart J
Year:
2019
Journal volume:
40
Journal issue:
37
Pages contribution:
3097-+
Fulltext / DOI:
doi:10.1093/eurheartj/ehz435
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/31504448
Print-ISSN:
0195-668X
TUM Institution:
Institut für Humangenetik
 BibTeX